Investment Thesis
Despite impressive top-line growth and operational profitability metrics, Carisma Therapeutics faces severe financial distress with negative shareholders' equity, liabilities exceeding assets, and substantial negative operating cash flow indicating the company is burning cash despite reported profitability. The disconnect between reported net income and negative cash flow, combined with weak liquidity (0.86x current ratio) and high long-term debt, suggests financial instability that outweighs the positive revenue growth.
Strengths
- Strong revenue growth of 31.5% year-over-year demonstrates market demand and business expansion
- High operating margin of 58.6% and net margin of 52.4% indicate efficient cost structure and pricing power
- Diluted EPS growth of 43.6% YoY shows improving earnings per share trajectory
Risks
- Negative shareholders' equity of -$867K indicates balance sheet insolvency and potential covenant violations or forced restructuring
- Operating cash flow of -$14.1M versus reported net income of $25.7M reveals severe cash generation problems and questions about earnings quality
- Current ratio of 0.86x indicates liquidity stress with liabilities exceeding current assets, limiting ability to meet near-term obligations
- Total liabilities of $7.4M exceed total assets of $6.6M by $800K, creating financial distress conditions
- Long-term debt of $10.0M against minimal asset base creates unsustainable leverage
Key Metrics to Watch
- Operating cash flow trend - critical to determine if negative cash burn improves or deteriorates
- Shareholders' equity trajectory - must return to positive territory to restore financial stability
- Current ratio and working capital position - essential to monitor liquidity crisis development
- Debt refinancing requirements - assess ability to service or refinance $10M long-term debt
Financial Metrics
Revenue
49.0M
Net Income
25.7M
EPS (Diluted)
$0.61
Free Cash Flow
-14.1M
Total Assets
6.6M
Cash
2.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
58.6%
Net Margin
52.4%
ROE
N/A
ROA
391.8%
FCF Margin
-28.7%
Balance Sheet & Liquidity
Current Ratio
0.86x
Quick Ratio
0.86x
Debt/Equity
N/A
Debt/Assets
113.2%
Interest Coverage
N/A
Long-term Debt
10.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-21T22:54:11.498121 |
Data as of: 2025-09-30 |
Powered by Claude AI